SE0103565D0 - Pharmaceutical formulation - Google Patents

Pharmaceutical formulation

Info

Publication number
SE0103565D0
SE0103565D0 SE0103565A SE0103565A SE0103565D0 SE 0103565 D0 SE0103565 D0 SE 0103565D0 SE 0103565 A SE0103565 A SE 0103565A SE 0103565 A SE0103565 A SE 0103565A SE 0103565 D0 SE0103565 D0 SE 0103565D0
Authority
SE
Sweden
Prior art keywords
pharmaceutical formulation
formulation
pharmaceutical
Prior art date
Application number
SE0103565A
Other languages
Swedish (sv)
Inventor
Nicola Bateman
Julie Cahill
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0103565A priority Critical patent/SE0103565D0/en
Publication of SE0103565D0 publication Critical patent/SE0103565D0/en
Priority to SK1203-2003A priority patent/SK12032003A3/en
Priority to KR10-2003-7012900A priority patent/KR20030087048A/en
Priority to CZ20032647A priority patent/CZ20032647A3/en
Priority to BR0208421-0A priority patent/BR0208421A/en
Priority to CNA028077474A priority patent/CN1536993A/en
Priority to EP02718317A priority patent/EP1381358B1/en
Priority to PL02365330A priority patent/PL365330A1/en
Priority to AT02718317T priority patent/ATE324886T1/en
Priority to US10/473,709 priority patent/US20040138299A1/en
Priority to NZ528284A priority patent/NZ528284A/en
Priority to CA002443040A priority patent/CA2443040A1/en
Priority to PCT/GB2002/001439 priority patent/WO2002080902A1/en
Priority to IL15795502A priority patent/IL157955A0/en
Priority to JP2002578941A priority patent/JP2004525164A/en
Priority to ES02718317T priority patent/ES2261655T3/en
Priority to DE60211139T priority patent/DE60211139T2/en
Priority to HU0303454A priority patent/HUP0303454A3/en
Priority to MXPA03008999A priority patent/MXPA03008999A/en
Priority to EEP200300476A priority patent/EE200300476A/en
Priority to IS6970A priority patent/IS6970A/en
Priority to NO20034386A priority patent/NO20034386L/en

Links

SE0103565A 2001-04-02 2001-10-25 Pharmaceutical formulation SE0103565D0 (en)

Priority Applications (22)

Application Number Priority Date Filing Date Title
SE0103565A SE0103565D0 (en) 2001-10-25 2001-10-25 Pharmaceutical formulation
EEP200300476A EE200300476A (en) 2001-04-02 2002-03-27 A solid pharmaceutical composition comprising 4-cyanotrifluoro-3- (4-fluorophenylsulfonyl) -2-hydroxy-2-methylpropiono-m-toluidide and PVP
NZ528284A NZ528284A (en) 2001-04-02 2002-03-27 Solid pharmaceutical composition comprising 4-cyano-trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropiono-m toluidide and PVP
PCT/GB2002/001439 WO2002080902A1 (en) 2001-04-02 2002-03-27 Solid pharmaceutical composition comprising 4 -cyano-trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropiono- m toluidide and pvp
CZ20032647A CZ20032647A3 (en) 2001-04-02 2002-03-27 Solid pharmaceutical composition containing 4-cyanotrifluoro-3-(4-fluorophenylsulfonyl)-2-hydroxy-2-methylpropiono-m-toluidine and PVP
BR0208421-0A BR0208421A (en) 2001-04-02 2002-03-27 Pharmaceutical formulation for mucosal administration to a patient, daily pharmaceutical dose, solid dispersion, use of pvp in solid dispersion with 4'-cyano-alpha ', alpha', alpha'-trifluoro-3- (4-fluoro phenylsulfonyl) - 2-hydroxy-2-methylpropiono-m-toluidide, and methods for increasing storage stability, bioavailability of the drug and for reducing the variation in plasma concentrations of 4'-cyano-alpha ', alpha', alpha ' , -trifluoro-3- (4-fluorophenylsulfonyl) -2-hydroxy-2-methylpropion-m-toluidide among patients
CNA028077474A CN1536993A (en) 2001-04-02 2002-03-27 Solid pharmaceutical composition comprising 4-cyano-trifluoro-N-[3-(40fluorophenylsulphonyl)2-hydroxy-2-methylpropiono]-m-toluidide and PVP
EP02718317A EP1381358B1 (en) 2001-04-02 2002-03-27 Solid pharmaceutical composition comprising 4'-cyano-trifluoro-3-(4-fluorophenylsulphonyl) -2-hydroxy-2-methylpropiono- m toluidide and pvp
PL02365330A PL365330A1 (en) 2001-04-02 2002-03-27 Solid pharmaceutical composition comprising 4 -cyano-trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropiono- m toluidide and pvp
AT02718317T ATE324886T1 (en) 2001-04-02 2002-03-27 SOLID MEDICINAL COMPOSITION CONTAINING 4'-CYANO-TRIFLUORO-3-(4-FLUOROPHENYLSULPHONYL) -2-HYDROXY- 2-METHYLPROPIONO- M TOLUIDIDE AND PVP
US10/473,709 US20040138299A1 (en) 2001-04-02 2002-03-27 Solid pharmaceutical composition comprising 4-cyano-trifluoro-3(4-fluorophenyl-sulphonyl)-2hydroxy-methylpropiono-m toluidide and pvp
SK1203-2003A SK12032003A3 (en) 2001-04-02 2002-03-27 Solid pharmaceutical composition comprising 4-cyano-trifluoro-3- (4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropiono-m toluidide and PVP
CA002443040A CA2443040A1 (en) 2001-04-02 2002-03-27 Solid pharmaceutical composition comprising 4 -cyano-trifluoro-3-(4-fluorophenyl-sulphonyl) -2-hydroxy-2-methylpropiono- m toluidide and pvp
KR10-2003-7012900A KR20030087048A (en) 2001-04-02 2002-03-27 Solid pharmaceutical composition comprising 4-cyano-trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropiono-m toluidide and pvp
IL15795502A IL157955A0 (en) 2001-04-02 2002-03-27 Solid pharmaceutical composition comprising 4-cyano-trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropiono-m toluidide and pvp
JP2002578941A JP2004525164A (en) 2001-04-02 2002-03-27 Solid pharmaceutical composition comprising 4-cyano-trifluoro-3- (4-fluorophenylsulfonyl) -2-hydroxy-2-methylpropiono-m-toluidide and PVP
ES02718317T ES2261655T3 (en) 2001-04-02 2002-03-27 SOLID PHARMACEUTICAL COMPOSITION INCLUDING 4'-CIANO-TRIFLUORO-3- (4-FLUOROFENILSULFONIL) -2-HIDROXI-2-METHYLPROPIONO-M-TOLUIDIDE AND PVP.
DE60211139T DE60211139T2 (en) 2001-04-02 2002-03-27 SOLID MEDICAMENT COMPOSITION CONTAINING 4'-CYANO-TRIFLUORO-3- (4-FLUORO-PHENYLSULPHONYL) -2-HYDROXY-2-METHYLPROPIONO- M TOLUIDIDE AND PVP
HU0303454A HUP0303454A3 (en) 2001-04-02 2002-03-27 Solid pharmaceutical composition comprising 4-cyano-trifluoro-3(4-fluorophenyl-sulphonyl)-2-hydroxy-2-methylpropiono-m toluidide and pvp
MXPA03008999A MXPA03008999A (en) 2001-04-02 2002-03-27 Solid pharmaceutical composition comprising 4 -cyano-trifluoro -3-(4 -fluorophenylsulphonyl) -2-hydroxy-2 -methylpropiono- m toluidide and pvp.
IS6970A IS6970A (en) 2001-04-02 2003-09-29 Solid formulation comprising 4-cyano-trifluoro-3- (4-fluorophenylsulfonyl) -2-hydroxy-2-methylpropion-m-toluidide and PVP
NO20034386A NO20034386L (en) 2001-04-02 2003-10-01 Solid pharmaceutical composition comprising 4-cyano-trifluoro-3- (4-fluorophenylsulfonyl) -2-hydroxy-2-methylpropiono-m-toluidide and PVP

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0103565A SE0103565D0 (en) 2001-10-25 2001-10-25 Pharmaceutical formulation

Publications (1)

Publication Number Publication Date
SE0103565D0 true SE0103565D0 (en) 2001-10-25

Family

ID=20285776

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0103565A SE0103565D0 (en) 2001-04-02 2001-10-25 Pharmaceutical formulation

Country Status (1)

Country Link
SE (1) SE0103565D0 (en)

Similar Documents

Publication Publication Date Title
NO20033384L (en) Pharmaceutical Formulation
NO20033785D0 (en) Pharmaceutical formulation
NO20033556L (en) Pharmaceutical Formulations
ITTO20010008A0 (en) PHARMACEUTICAL FORMULATION
FI20011478A (en) Pharmaceutical composition
PT1501534E (en) PHARMACEUTICAL FORMULATIONS
NO20035627D0 (en) Pharmaceutical formulation
EE200300589A (en) Pharmaceutical compositions
DE50209245D1 (en) NEUROPROTEKTIVES MEDICAMENT
FI20022128A (en) Pharmaceutical composition
NO20042502L (en) Pharmaceutical formulation comprising bicalutamide
NO20041485L (en) Pharmaceutical formulation comprising (R) -bicalutamide
AR025867A1 (en) PHARMACEUTICAL PORTASDORA FORMULATION
DE10291905D2 (en) Pharmaceutical composition
NO20015534D0 (en) Pharmaceutical mixer
EE200300465A (en) Pharmaceutical compositions based on pyridoindolone derivatives
DE10107261B4 (en) Pharmaceutical composition
NO20041236L (en) Pharmaceutical Formulation
FI20012242A0 (en) New pharmaceutical compounds
SE0102957D0 (en) Pharmaceutical formulation
SE0102572D0 (en) Pharmaceutical formulation
SE0101171D0 (en) Pharmaceutical formulation
SE0101326D0 (en) Pharmaceutical formulation
SE0101325D0 (en) Pharmaceutical formulation
SE0103565D0 (en) Pharmaceutical formulation